EarningsQ2 2026 Earnings Report
PROF Q2 2026 EPS Results
Actual EPS-$0.26
Consensus EPS-$0.24
Beat/MissMissed by -$0.02
One Year Ago EPS-$0.52
PROF Q2 2026 Revenue Results
Actual Revenue$2.41M
Expected Revenue$4.75M
Beat/MissMissed by -$2.34M
YoY Revenue Growth+12.27%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
PROF Upcoming Earnings
Profound Medical's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: improving revenue trends (when adjusted for a one-time shipment timing shift), high gross margins, declining operating expenses, a growing $70M qualified sales pipeline, expanding payer coverage (Q1+Q2 added ~26.8M covered lives and Medicare tailwinds), and compelling randomized clinical evidence (CAPTAIN) that differentiates TULSA on quality-of-life outcomes. Challenges include a $3.1M revenue recognition timing slip, short-term utilization dips at a few sites during model transitions, installation/logistics lags, a proposed ASC reimbursement reduction to monitor, and continued net losses though improving. On balance, the positives — notably the sizable pipeline, reimbursement tailwinds, high margins, and strengthening clinical data — materially outweigh the operational and timing headwinds.Company Guidance
Revenue Growth (Reported and Adjusted)
Reported Q2 FY26 revenue of $2.5M (recurring $1.6M; capital equipment $0.871M), a 12% increase versus $2.2M in Q2 FY25. Excluding a $3.1M shipment timing shift, Q2 revenue would have been ~$5.6M, representing ~153% year-over-year growth.
Full-Year Guidance and Growth Outlook
Company reiterated FY26 revenue guidance of approximately $25M, which represents ~56% growth versus prior year, driven by record order activity and an expanding pipeline.
Improving Profitability Metrics
Q2 FY26 gross margin was ~78% versus ~73% in the comparable prior period, and operating expenses declined to $13M (down 16% vs $15.4M in Q2 FY25). Net loss improved to $9.5M ($0.26/share) from $15.7M ($0.52/share) year-over-year.
Strong Cash Position
As of June 30, 2026, ProFound held $38.3M in cash, supporting ongoing commercialization and operational investments.
Commercial Momentum and Pipeline
TULSA PRO install base reached 84 systems at end of Q2. Qualified sales pipeline is ~ $70M (within verify/ negotiate/ contract stages), roughly 90% TULSA PRO and 10% Sonalleve, with ~70% US / 30% international split.
Record Demand and Lead Generation
July set another monthly record for new orders; SRS-26 generated ~160 qualified leads over 4 days. Management reports momentum continued into Q3.
Reimbursement Tailwinds
CMS proposed OPPS rule would increase TULSA hospital payment ~14.9% to $15.5K/procedure (creating a ~44% premium vs HIFU/Aquablation and ~26% vs robotic RP under proposal). Physician payment parity also largely maintained; expanded payer coverage added ~18.3M covered lives in Q2 (after ~8.5M in Q1).
Robust Clinical Evidence (CAPTAIN Trial)
CAPTAIN trial demonstrated TULSA's statistically superior quality-of-life outcomes vs robotic radical prostatectomy, achieving primary safety endpoint and better composite urinary continence and erectile function at 6 months. Additional data show superior perioperative outcomes (no blood loss, no overnight stay, faster recovery) and preservation of penile length (median no change vs 0.65 cm reduction for robotic at 1 month).
Strategic Technology and Partnerships
Plans for FDA clearance to integrate TULSA with Siemens Free.Max iMRI early next year and collaboration with Illuccix to explore PSMA PET integration into treatment planning, enhancing imaging-guided targeting and potential growth in 2027.
PROF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed